These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

299 related items for PubMed ID: 25099702

  • 1. Pharmacodynamic monitoring of mammalian target of rapamycin inhibition by phosphoflow cytometric determination of p70S6 kinase activity.
    Hoerning A, Wilde B, Wang J, Tebbe B, Jing L, Wang X, Jian F, Zhu J, Dolff S, Kribben A, Hoyer PF, Witzke O.
    Transplantation; 2015 Jan; 99(1):210-9. PubMed ID: 25099702
    [Abstract] [Full Text] [Related]

  • 2. P70S6 kinase phosphorylation: a new site to assess pharmacodynamy of sirolimus.
    Wang JY, Fan H.
    Chin Med J (Engl); 2015 Mar 05; 128(5):664-9. PubMed ID: 25698201
    [Abstract] [Full Text] [Related]

  • 3. Performance of a phosphoflow assay to determine phosphorylation of S6 ribosomal protein as a pharmacodynamic read out for mTOR inhibition.
    Abdel-Kahaar E, Kabakchiev M, Hartmann B, Wieland E, Shipkova M.
    Clin Biochem; 2016 Oct 05; 49(15):1181-1187. PubMed ID: 27372285
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Sirolimus did not affect CD4(+)CD25(high) forkhead box p3(+)T cells of peripheral blood in renal transplant recipients.
    Chu ZQ, Ji Q.
    Transplant Proc; 2013 Oct 05; 45(1):153-6. PubMed ID: 23375290
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Oscillatory mTOR inhibition and Treg increase in kidney transplantation.
    Sabbatini M, Ruggiero G, Palatucci AT, Rubino V, Federico S, Giovazzino A, Apicella L, Santopaolo M, Matarese G, Galgani M, Terrazzano G.
    Clin Exp Immunol; 2015 Nov 05; 182(2):230-40. PubMed ID: 26077103
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Different immunosuppressive combinations on T-cell regulation in renal transplant recipients.
    Fourtounas C, Dousdampanis P, Sakellaraki P, Rodi M, Georgakopoulos T, Vlachojannis JG, Mouzaki A.
    Am J Nephrol; 2010 Nov 05; 32(1):1-9. PubMed ID: 20484893
    [Abstract] [Full Text] [Related]

  • 10. Monitoring biological action of rapamycin in renal transplantation.
    Leogrande D, Teutonico A, Ranieri E, Saldarelli M, Gesualdo L, Schena FP, Di Paolo S.
    Am J Kidney Dis; 2007 Aug 05; 50(2):314-25. PubMed ID: 17660033
    [Abstract] [Full Text] [Related]

  • 11. Comparison of regulatory T cells and FoxP3-positive T-cell subsets in the peripheral blood of renal transplant recipients with sirolimus versus cyclosporine: a preliminary study.
    Zhao T, Yang C, Qiu Y, Xue Y, Zhao Z, Song D, Qiu Y, Ma Z, Yang B, Xu M, Rong R, Zhu T.
    Transplant Proc; 2013 Aug 05; 45(1):148-52. PubMed ID: 23375289
    [Abstract] [Full Text] [Related]

  • 12. Differential Effects of Calcineurin and Mammalian Target of Rapamycin Inhibitors on Alloreactive Th1, Th17, and Regulatory T Cells.
    Gallon L, Traitanon O, Yu Y, Shi B, Leventhal JR, Miller J, Mas V, L X, Mathew JM.
    Transplantation; 2015 Sep 05; 99(9):1774-84. PubMed ID: 25905982
    [Abstract] [Full Text] [Related]

  • 13. Biochemical monitoring of mTOR inhibitor-based immunosuppression following kidney transplantation: a novel approach for tailored immunosuppressive therapy.
    Hartmann B, Schmid G, Graeb C, Bruns CJ, Fischereder M, Jauch KW, Heeschen C, Guba M.
    Kidney Int; 2005 Dec 05; 68(6):2593-8. PubMed ID: 16316335
    [Abstract] [Full Text] [Related]

  • 14. Increased interleukin-10 production without expansion of CD4+CD25+ T-regulatory cells in early stable renal transplant patients on calcineurin inhibitors.
    Mittal SK, Sharma RK, Gupta A, Naik S.
    Transplantation; 2009 Aug 15; 88(3):435-41. PubMed ID: 19667950
    [Abstract] [Full Text] [Related]

  • 15. Assessing the efficacy of mammalian target of rapamycin inhibitors by phosphorylation of p70S6K in CD4-positive cells of liver transplant patients.
    Wang JY, Fan H.
    Medicine (Baltimore); 2019 Oct 15; 98(43):e17457. PubMed ID: 31651849
    [Abstract] [Full Text] [Related]

  • 16. The influence of immuosuppressive therapy on the development of CD4+CD25+ T cells after renal transplantation.
    Korczak-Kowalska G, Wierzbicki P, Bocian K, Klosowska D, Niemczyk M, Wyzgal J, Korecka A, Durlik M, Chmura A, Paczek L, Górski A.
    Transplant Proc; 2007 Nov 15; 39(9):2721-3. PubMed ID: 18021968
    [Abstract] [Full Text] [Related]

  • 17. Quantitative analysis of regulatory T cells in kidney graft recipients: a relationship with calcineurin inhibitor level.
    Calvo-Turrubiartes M, Romano-Moreno S, García-Hernández M, Chevaile-Ramos JA, Layseca-Espinosa E, González-Amaro R, Portales-Pérez D.
    Transpl Immunol; 2009 May 15; 21(1):43-9. PubMed ID: 19233271
    [Abstract] [Full Text] [Related]

  • 18. Affects of immunosuppression on circulating dendritic cells: an adjunct to therapeutic drug monitoring after heart transplantation.
    Barten MJ, Garbade J, Bittner HB, Fiedler M, Dhein S, Thiery J, Mohr FW, Gummert JF.
    Int Immunopharmacol; 2006 Dec 20; 6(13-14):2011-7. PubMed ID: 17161355
    [Abstract] [Full Text] [Related]

  • 19. Immune monitoring with a lymphocyte adenosine triphosphate assay in kidney transplant recipients treated with a calcineurin inhibitor.
    Sugiyama K, Tsukaguchi M, Toyama A, Satoh H, Saito K, Nakagawa Y, Takahashi K, Tanaka S, Onda K, Hirano T.
    Exp Clin Transplant; 2014 Jun 20; 12(3):195-9. PubMed ID: 24907718
    [Abstract] [Full Text] [Related]

  • 20. Immunosuppressive effects of DTCM-G, a novel inhibitor of the mTOR downstream signaling pathway.
    Shibasaki S, Yamashita K, Goto R, Wakayama K, Tsunetoshi Y, Zaitsu M, Igarashi R, Haga S, Ozaki M, Umezawa K, Todo S.
    Transplantation; 2013 Feb 27; 95(4):542-50. PubMed ID: 23269193
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.